Associated Papers
Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.
Nakamura H et al.
Histopathology, 2025
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.
Mekhamer AM et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2024
Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon.
Hamadeh LN et al.
Gene, 2023
Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.
Ong HW et al.
Acs Chemical Neuroscience, 2023
37084253 (PubMed )
Supplement: cn3c00135_si_001.pdf
Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus.
Vestergaard LK et al.
Cancers, 2021
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Spaans VM et al.
Gynecologic Oncology, 2018
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G et al.
Plos One, 2015
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA et al.
Hematology/oncology and Stem Cell Therapy, 2014
Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.
Sherwood JL et al.
Plos One, 2014
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K et al.
Cancer Research, 2005
Select a paper to view details